WO2014096440A3 - Albumin composition for preventing and/or reducing formation of peptide fibrils - Google Patents
Albumin composition for preventing and/or reducing formation of peptide fibrils Download PDFInfo
- Publication number
- WO2014096440A3 WO2014096440A3 PCT/EP2013/077869 EP2013077869W WO2014096440A3 WO 2014096440 A3 WO2014096440 A3 WO 2014096440A3 EP 2013077869 W EP2013077869 W EP 2013077869W WO 2014096440 A3 WO2014096440 A3 WO 2014096440A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preventing
- reducing formation
- albumin composition
- peptide fibrils
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention concerns compositions comprising highly purified albumin suitable for preventing and/or reducing of peptide fibrillation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12198965.1 | 2012-12-21 | ||
EP12198965 | 2012-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014096440A2 WO2014096440A2 (en) | 2014-06-26 |
WO2014096440A3 true WO2014096440A3 (en) | 2014-08-14 |
Family
ID=49880802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/077869 WO2014096440A2 (en) | 2012-12-21 | 2013-12-20 | Composition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014096440A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198971B2 (en) | 2012-01-09 | 2015-12-01 | Adocia | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid |
US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
WO2017211917A1 (en) | 2016-06-07 | 2017-12-14 | Adocia | Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid |
FR3072875B1 (en) * | 2017-10-31 | 2020-11-06 | Adocia | COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS |
WO2019086559A1 (en) * | 2017-10-31 | 2019-05-09 | Adocia | Composition comprising a glp-2 receptor agonist and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals |
FR3079414B1 (en) * | 2018-03-27 | 2020-05-01 | Adocia | COMPOSITION COMPRISING A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS |
CN111670042A (en) | 2017-12-07 | 2020-09-15 | 阿道恰公司 | Compositions in the form of injectable aqueous solutions comprising human glucagon and a polyamino acid copolymer |
WO2019110838A1 (en) | 2017-12-07 | 2019-06-13 | Adocia | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid |
FR3083087A1 (en) | 2018-06-29 | 2020-01-03 | Adocia | COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID |
MX2020005915A (en) | 2017-12-07 | 2020-10-19 | Adocia | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid. |
US10987426B2 (en) | 2017-12-07 | 2021-04-27 | Adocia | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid |
FR3067247A1 (en) | 2018-06-07 | 2018-12-14 | Adocia | COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID |
JP2022552655A (en) | 2019-10-07 | 2022-12-19 | キャリーオペ,インク. | GPR119 agonist |
UY39222A (en) | 2020-05-19 | 2021-11-30 | Kallyope Inc | AMPK ACTIVATORS |
EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope Inc | Ampk activators |
WO2022157747A2 (en) | 2021-01-25 | 2022-07-28 | Mylan Ireland Limited | Pharmaceutical peptide compositions and methods of preparation thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019260A1 (en) * | 1991-05-07 | 1992-11-12 | Tomas Moks | Peptide hormone solution |
WO1999047160A1 (en) * | 1998-03-13 | 1999-09-23 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
WO2003066681A1 (en) * | 2002-02-05 | 2003-08-14 | Delta Biotechnology Limited | Stabilization of protein preparations |
WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
WO2005058958A2 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
WO2006128083A2 (en) * | 2005-05-25 | 2006-11-30 | Curedm, Inc. | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
-
2013
- 2013-12-20 WO PCT/EP2013/077869 patent/WO2014096440A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019260A1 (en) * | 1991-05-07 | 1992-11-12 | Tomas Moks | Peptide hormone solution |
WO1999047160A1 (en) * | 1998-03-13 | 1999-09-23 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
WO2003066681A1 (en) * | 2002-02-05 | 2003-08-14 | Delta Biotechnology Limited | Stabilization of protein preparations |
WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
WO2005058958A2 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
WO2006128083A2 (en) * | 2005-05-25 | 2006-11-30 | Curedm, Inc. | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
Non-Patent Citations (5)
Title |
---|
KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664 - 1669, XP002201014, ISSN: 0022-2623, DOI: 10.1021/JM9909645 * |
M. I. IVANOVA ET AL: "Molecular basis for insulin fibril assembly", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 45, 10 November 2009 (2009-11-10), pages 18990 - 18995, XP055080001, ISSN: 0027-8424, DOI: 10.1073/pnas.0910080106 * |
PHUONG TRAN ET AL: "Recombinant albumin: characterization as a pharmaceutical excipient in the stabilization of therapeutic protein products", 23 March 2010 (2010-03-23), XP055106166, Retrieved from the Internet <URL:http://www.biopharma.novozymes.com/en/information-centre/posters-and-presentations/Documents/Abdev10poster_phut_230310.pdf> [retrieved on 20140307] * |
RODRIGUES ANANDA LAGES ET AL: "Does GLP-2 infusion reduce colon injury and improve protein nutritional status of piglets with colitis?", FASEB JOURNAL, vol. 25, April 2011 (2011-04-01), & EXPERIMENTAL BIOLOGY MEETING 2011; WASHINGTON, DC, USA; APRIL 09 -13, 2011, XP009177982 * |
TUE RASMUSSEN ET AL: "The Molecular Chaperone Î+--Crystallin as an Excipient in an Insulin Formulation", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 27, no. 7, 24 March 2010 (2010-03-24), pages 1337 - 1347, XP019827960, ISSN: 1573-904X * |
Also Published As
Publication number | Publication date |
---|---|
WO2014096440A2 (en) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014096440A3 (en) | Albumin composition for preventing and/or reducing formation of peptide fibrils | |
JOP20180103B1 (en) | PHARMACEUTICAL COMPOSITION of CARBETOCIN | |
WO2015038796A3 (en) | Secretion of heme-containing polypeptides | |
MX2015011898A (en) | Pyrazolo compounds and uses thereof. | |
PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
WO2015004534A3 (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
WO2012140274A3 (en) | Agonists and antagonists of the wnt pathway | |
MY181898A (en) | Heterocyclic compounds and uses thereof | |
EP3725811A3 (en) | Compositions for inhibiting masp-2 dependent complement activation | |
WO2011130222A3 (en) | Compositions and methods comprising variant proteases | |
WO2015120062A3 (en) | Therapeutic compounds and compositions | |
WO2014145519A3 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency | |
WO2011121576A3 (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
NZ706838A (en) | Use of p3 of bacteriophage fusion proteins as amyloid binding agents | |
WO2013072901A3 (en) | Compositions and methods for treating glioma | |
MX362175B (en) | Use of p3 of bacteriophage as amyloid binding agents. | |
WO2015092810A3 (en) | Amorphous form of idelalisib | |
EP3046902A4 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
WO2014186450A3 (en) | Highly potent inhibitors of porcupine | |
CN106687453A8 (en) | As the tetrahydroquinoline derivative of bromine domain inhibitor | |
MX361233B (en) | C-terminal hsp90 inhibitors. | |
EP3046901A4 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
CA2904166C (en) | Formulations with reduced oxidation | |
EP3037091A4 (en) | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13811982 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13811982 Country of ref document: EP Kind code of ref document: A2 |